

# Members Obtain Free CE Credits from JCP Articles!



## ***Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19***

February 2024 – *The Journal of Clinical Pharmacology* (JCP)

### **Why is this article important to you?**

This activity aims to deepen healthcare professionals' knowledge on nirmatrelvir/ritonavir, focusing on hepatic impairment's impact, safety assessment, dosing considerations and practical application in COVID-19 management.



### **ACPE Accreditation Statement**

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

**UAN:** 0665-0000-24-001-H01-P – ACPE 1 Contact Hours

**Activity Type:** Knowledge-based **Format:** Home-study **Target Audience:** 'P'



**ACCME**  
ACCREDITED

### **ACCME Accreditation Statement**

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### **ACCME Designation Statement**

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### **Target Audience**

Interprofessional team of Physicians, Pharmacists, PhDs and Nurses interested in expanding their knowledge on nirmatrelvir/ritonavir, focusing on hepatic impairment's impact, safety assessment, dosing considerations and practical application in COVID-19 management.

### **Learning Objectives**

After completing this activity, the learner will be able to:

1. Identify three key pharmacokinetic interactions between nirmatrelvir and ritonavir, with a focus on the role of cytochrome P450 3A4.
2. Describe the safety profile of nirmatrelvir/ritonavir in individuals with hepatic impairment by interpreting observable parameters, laboratory measurements and assessments.
3. Interpret the study findings to determine whether dose adjustments are warranted in individuals with hepatic impairment when using nirmatrelvir/ritonavir for mild to moderate COVID-19 treatment.
4. Apply the outcomes of the Phase 1 study to real-world clinical scenarios, making informed decisions about the use of nirmatrelvir/ritonavir in managing COVID-19 in individuals with hepatic impairment.

### **Requirements to Receive Credit**

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the

---

ACCP is a Member-focused/Member-driven clinical pharmacology society with [Member Benefits](#) that enhance your professional growth. [Join today!](#)

---

online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact [CE@ACCP1.org](mailto:CE@ACCP1.org) with any questions.

#### **Disclosures:**

Article Selection: John van den Anker, MD, PhD, Editor-in-Chief, JCP, selected the article for this course and has nothing to disclose.  
Planner: Mirshad PV, PhD, Associate Professor, MES Medical Coll, Kerala, India, planned the continuing education documentation for this course and has nothing to disclose.  
CE Reviewer: Kenneth Der, BS, Associate Director, Amgen Inc, served as the CE Reviewer and all of the relevant financial relationships listed for this individual have been mitigated.

#### **Schedule & Fees**

JCP monthly Journal CE articles are generally released on the 1<sup>st</sup> or 2<sup>nd</sup> Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

#### **Acknowledgement of Financial Support**

No financial support was received for this educational activity.

#### **Home Study Initial Release and Expiration Dates**

**Date of Issuance:** 2/1/2024

**Expiration Date:** 2/1/2027

#### **Online Location:**

<https://ce.accp1.org/products/2024-accp-journal-of-clinical-pharmacology-journal-ce-monthly-ce-offerings>